# GOLDENWELL BIOTECH, INC. (GWLL) · Edgar & Edgarette company card

> Goldenwell Biotech (GWLL) saw revenue fall 60.4% in FY2025 to $0 million, operating margin -206047% against a 7.3% median for food and kindred products, equity -952% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1800373 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/GWLL) · [JSON](https://www.pops4.com/boards/company/GWLL.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $55 |
| Revenue growth, 1 year | -60.4% |
| Revenue growth per year | -75.8% |
| Operating margin | -206047.3% (prior year -88559.7%) |
| Net margin | -539038.2% |
| Operating cash flow | −$22,629 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $26,775 |
| Long-term debt | — |
| Total assets | $36,120 |
| Total equity | −$343,713 |
| Equity ÷ assets | -951.6% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, earlier statements no longer to be relied on, late quarterly report notice, auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$23K in FY2025); operating loss: a margin of -206047.3% in FY2025; revenue is hard to predict: its 80% range is ±90%

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: revenue down 60.4% on the year, down 75.8% a year over 4 years; operating margin -206047.3%, down from -88559.7%. Soundness: equity -951.6% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $0K to $0K. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, food and kindred products): operating margin -206047.3% against a 7.3% median; growth -60.4% against 4.4%.

Range logged 2026-09-30, receipt d8b4f34a57307f87, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226001748/0001477932-26-001748-index.htm))
- Item 4.02 Earlier statements no longer to be relied on: 1, latest 2026-05-27 ([filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226003440/0001477932-26-003440-index.htm))
- Item NT 10-Q Late quarterly report notice: 1, latest 2026-05-12 ([filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226002962/0001477932-26-002962-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-09-29 ([filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226005892/0001477932-26-005892-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-10-09 ([filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226006138/0001477932-26-006138-index.htm))

## Recent filings

- 8-K · filed 2026-10-09 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226006138/0001477932-26-006138-index.htm)
- 8-K · filed 2026-09-29 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226005892/0001477932-26-005892-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226005067/0001477932-26-005067-index.htm)
- 10-Q · filed 2026-07-01 · [filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226004131/0001477932-26-004131-index.htm)
- 10-K · filed 2026-07-01 · [filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226004130/0001477932-26-004130-index.htm)
- 8-K · filed 2026-05-27 · 4.02 Non-Reliance on Previously Issued Financial Statements; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1800373/000147793226003440/0001477932-26-003440-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001800373.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1800373

## Cite

POPS4, Edgar & Edgarette: GOLDENWELL BIOTECH, INC. (GWLL) company card, from the company's own SEC filings, accessed 2026-11-14, https://www.pops4.com/boards/company/GWLL. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.